Drugs / [68Ga]CBP8

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03535545 Aug 2018 → Jun 2027 expected lung cancer, pulmonary fibrosis Massachusetts General Hospital Recruiting No outcome recorded
Phase 24 trials
Phase 2 NCT07572383 May 2026 → Dec 2028 expected pulmonary fibrosis Peter Caravan Recruiting No outcome recorded
Phase 2 NCT06532071 Jan 2025 → Dec 2028 expected pulmonary fibrosis Peter Caravan Recruiting No outcome recorded
Phase 2 NCT05417776 Sep 2022 → Oct 2026 expected interstitial lung disease Massachusetts General Hospital Recruiting No outcome recorded
Phase 2 NCT04485286 Jul 2020 → May 2027 expected drug or radiation exposure-related interstitial lung disease, lung cancer, malignant pancreatic neoplasm Massachusetts General Hospital Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT05619302 Jan 2023 → Dec 2026 expected amyloidosis Brigham and Women's Hospital Active not recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as 68Ga-CBP8 “The human analog probe targeted against type 1 collagen, 68Ga-CBP8, was tested on excised human lung tissue containing RILI and quantified via autoradiography.” PMID 37808864 Sep 2023
7

“The 68Ga-Collagen Binding Probe #8, 68Ga-CBP8, is a peptide-based, type I collagen-targeted probe developed for imaging of tissue fibrosis.” PMID 37116909 Dec 2022

NCT06532071

NCT03535545

NCT04485286

NCT05417776

NCT07572383

NCT05619302

Known as 68Ga-Collagen Binding Probe #8 “The 68Ga-Collagen Binding Probe #8, 68Ga-CBP8, is a peptide-based, type I collagen-targeted probe developed for imaging of tissue fibrosis.” PMID 37116909 Dec 2022
Modality Diagnostic / imaging agent “The 68Ga-Collagen Binding Probe #8, 68Ga-CBP8, is a peptide-based, type I collagen-targeted probe developed for imaging of tissue fibrosis.” PMID 37116909 Dec 2022
Route Intravenous “will be administered intravenously” NCT05417776